Qorvo Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing

Read More

Press Releases

Qorvo Biotechnologies Receives FDA Emergency Use Authorization (EUA) for Rapid COVID-19 Antigen Testing

Read More

Qorvo Biotechnologies Awarded $24.4 Million National Institutes of Health Contract to Scale Point-of-Care COVID-19 Antigen Testing

Read More

Technical Support

Download necessary documents such as test cartridge Instructions for Use, the Qorvo Omnia Instrument Operating Manual, Quick Start Guides and Safety Datasheets (SDS).

Qorvo BAW Technology

Learn how Qorvo Bulk Acoustic Wave (BAW) technology is revolutionizing the diagnostic testing landscape.


About Qorvo Biotechnologies

Qorvo Biotechnologies, LLC is a wholly owned subsidiary of Qorvo, Inc. focused on the development of point-of-care (POC) diagnostics solutions leveraging Qorvo’s innovative BAW sensor technology.

About Qorvo

Qorvo makes a better world possible by providing innovative radio frequency (RF) solutions at the center of connectivity. We combine product and technology leadership, systems-level expertise and global manufacturing scale to quickly solve our customers’ most complex technical challenges. Qorvo serves diverse high-growth segments of large global markets, including advanced wireless devices, wired and wireless networks, and defense radar and communications. We also leverage unique competitive strengths to advance 5G networks, cloud computing, the Internet of Things and other emerging applications that expand the global framework interconnecting people, places and things.

Learn More at Qorvo.com

Contact Us

Please submit the form so we can get back to you.